In light of findings that women with psoriasis are more likely than men to discontinue biological therapies for psoriasis, researchers attempted to identify possible differences in satisfaction with biological treatment between female and male patients.

Researchers obtained data for psoriasis patients treated with biologics from the prospective, multicentre, daily-practice BioCAPTURE registry. Responses to the Treatment Satisfaction Questionnaire for Medication (TSQM) were analyzed.

A total of 315 patients with 396 corresponding treatment episodes were included. Of these, roughly forty percent were women. Women had significantly lower baseline PASI scores. Over one year of treatment, women had lower TSQM scores for “side-effects” and “global satisfaction,” compared with men. Researchers determined that women “reported more relevant adverse events in the context of biologic treatment compared to men.” Women had more instances of fungal and herpes simplex infections.

— J Eur Acad Dermatol Venereol. 33(10):1913-1920